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Purpose: This work investigated the delivery accuracy of high-dose lung and spine stereotactic 
treatments delivered with the Elekta Infinity and Versa HD platforms. The accuracy of these platforms will 
be used for consideration in implementing a spine stereotactic radiosurgery (SSRS) program at Mary Bird 
Perkins Cancer Center.  
Methods: A geometric phantom was used to perform Winston-Lutz type tests that assessed the relevant 
degrees of freedom (gantry, collimator, and couch) of the delivery system. A lung stereotactic body 
radiation therapy (SBRT) and spine SRS treatment plan were generated for use in end-to-end testing. 
Delivery accuracy was tested using a novel diode array design, which achieved a spatial resolution of 1 
mm along a single axis. On board imaging aided in setup of the diode array to the desired position before 
commencing treatment delivery. The  delivered dose distribution and calculated planar dose distributions 
were compared and analyzed. Several metrics were analyzed from the overlaid profiles, including: 
percent difference between calculated and measured field centers, and comparison of spatial shifts of the 
75% and 60% isodose levels. Percent difference between a calculated and measured point dose 
quantified discrepancies for the approximate region of the spinal cord. Calculated dose profiles and shifts 
at the 60 and 75% isodose levels indicated distortions in the profiles. 
Results:   All machines demonstrated an MV Isocenter radius for gantry and treatment table rotation less 
than 0.70 mm as limited by the Elekta customer acceptance protocol. For SSRS plans, percent difference 
of the point representing the spinal cord produced results that were consistently higher as a result of a 
higher dose delivery than calculated. All lung SBRT and SSRS deliveries were capable of achieving an 
average of 1-mm accuracy. Moreover, profiles showed that the measured profile fell within the planned 
profile, suggesting a systematic distortion in the profiles. 
Conclusion: Based on the findings of this project, the Elekta Infinity and Versa HD delivery systems were 
adequate for lung SBRT treatments but require further exploration for the commencement of spine SRS 




Chapter 1. Introduction 
1.1 Background and Significance 
1.1.1 Stereotactic Body Radiation Therapy 
 Stereotactic Body Radiation Therapy (SBRT) is a non-invasive cancer treatment where high 
doses of external beam radiation are delivered in a limited number of fractions to extra-cranial sites. 
SBRT derived from stereotactic radiosurgery (SRS), which was originally used to treat intracranial and 
spinal tumors as well as other disorders of the brain with the use of body frames and three- dimensional 
imaging to localize lesions (Khan, 2010).  Since the advent of on-board imaging, SBRT has become a 
feasible treatment options since body frames are not required for treatments. Systems now utilize x-ray 
imaging of bony anatomy and implanted fiducial marker to localize the target (Khan, 2010). Reductions in 
errors and uncertainties in patient positioning and targeting have been made possible due to image 
guided radiation therapy (IGRT) (Court et al., 2008). IGRT has provided new capabilities of treatment that 
have increased dose delivery precision to the target and avoidance of organs at risk (OAR). This is 
achievable since image guidance can be utilized before, during, or after any radiation therapy treatment. 
Implementation of beam shaping and image guidance technology have enhanced the performance of 
SBRT in reducing safety margins and precisely conforming to the tumor outline in all three dimensions 
(Greco et al., 2015). The additional confidence that IGRT provides for patient positioning has been crucial 
in implementing innovative treatments to ablate tumors, such as with stereotactic body radiation therapy 
(Greco et al., 2015).  
A typical SBRT plan will vary from a conventional radiotherapy plan in several ways. SBRT plans employ 
1 to 5 fractions with doses ranging from 6 to 30 Gy per fraction, whereas conventional treatments use 
anywhere from 10 to 30 treatments with doses ranging from 1.8 to 3Gy per fraction (Benedict et al., 
2010). Typically those treatments with only one treatment fraction are termed stereotactic radiosurgery 
because of its similar outcome to surgery without invasive means. Target definition also varies for the two 
treatment plans. Conventional radiotherapy treatments will treat tumors that may not have sharp 
boundaries, which are accounted for with margins on the order of centimeters, whereas SBRT treatments 
require tumors to be well defined with any additional margins on the order of millimeters due to the high, 
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conformal dose of the target volume (Benedict et al., 2010). Targeting and conformity requirements are 
higher for SBRT and SRS treatments because of the larger doses delivered in fewer fractions, meaning 
that inaccurate targeting will have a greater effect on normal tissues with stereotactic treatments. Also, 
SBRT treatments typically employ more beams than conventional treatments in order to achieve this 
degree of conformality. In addition to the number of beams, delivery techniques such as noncoplanar 
beam arrangements, inhomogeneous dose distributions, and IMRT are often used for SBRT treatments in 
order to minimize the dose to surrounding normal tissue (Benedict et al., 2010).   
Whereas conventional radiotherapy delivers a prescribed dose to large volumes over many small-dose 
fractions spanning months, SBRT delivers the prescription dose to smaller target volumes via 
hypofractionation (Benedict et al., 2010). Hypofractionation utilizes a higher dose per fraction to increase 
the biologically effective dose (BED), which is used to evaluate the effects of different fractionation 
schedules because it varies according to dose per fraction, number of fractions, and tissue 
characteristics. In order for the objective of ablative radiation therapy to be met, as opposed to regional 
adjuvant therapy for cancers such as rectum, breast, and sarcoma that have been treated by other 
means such as surgery and chemotherapy, the dose prescription must radically change by increasing the 
dose and decreasing the number of fractions (Papiez and Timmerman, 2008). The result is an ablative 
dose per fraction where damage to adjacent critical structures is avoided by maintaining a sharp dose fall-
off around the target (Amini et al., 2014). When effects of equivalent total doses with different 
fractionation regimens are compared, they produce unequal biological effects (Kong et al., 2014). 
Achieving a high BED has been shown to increase overall survival by improving tumor control rate for 
non-small cell lung cancer, paraspinal and spinal metastasis, and oligometastastic liver disease (Kong et 
al., 2014; Zhang et al., 2011; Sheehan and Jagannathan, 2008; Berkovic et al., 2017). Due to the ablative 
nature of SBRT, this hypofractionated approach more closely follows the model of surgery than 
conventional radiotherapy. This makes SBRT an attractive option for patients unwilling or incapable of 
undergoing surgery (Papiez and Timmerman, 2008). Specifically, SBRT has been proven highly effective 
for controlling specific cancers of the thorax, abdomen, and spine (Benedict et al., 2010; Nalichowski et 
al., 2017).  
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1.1.2 Lung Cancer  
 As shown in Figure 1.1, lung cancer is estimated to be the second cancer in terms of incidence 
and the leading cause of cancer death within the United States, accounting for approximately 25% of 
estimated deaths for both men and women (American Cancer Society, 2018). In order to treat this 
prevalent cancer, primary tumor control becomes the essential requirement for the treatment of lung 
cancer (Timmerman et al., 2010). Long-term follow up of patients treated with conventional fractionation 
techniques for non-small cell lung cancer showed that only 20-30% of these tumors stopped growth or 
recessed (Papiez and Timmerman, 2008). Moreover, it has been shown that patients with early stage, 
medically inoperable lung cancer have low primary tumor control rates of approximately 30-40% 
(Timmerman et al., 2010). According to Timmerman et al.’s findings, SBRT delivered according Radiation 
Therapy Oncology Group Report 0236 to early stage lung cancer patients provided more than double the 
rate of primary tumor control than reports describing conventional radiotherapy. 
 
Figure 1.1. 2018 Estimates for Leading Sites of New Cancer Cases and Deaths in the United States 
(American Cancer Society, 2018). 
 
 It is believed that the hypofractionated doses in SBRT contribute to an improved local control via 
clonogenic cell death from DNA strand breaks, chromosome aberrations, and vascular damage in tumors 
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that lead to indirect cell death (Song et al., 2013). Since SBRT delivers a much higher BED than 
conventional therapy, it has been shown to lead to long survival and local tumor control for patients with 
non-small cell lung cancer (Kong et al., 2014).  
1.1.3 Spinal Metastases 
 It is estimated that approximately 10% of cancer patients will develop vertebral or spinal 
metastases, typically originating from primary breast, lung, prostate, and renal cell carcinomas (Greco et 
al., 2015).  This type of metastasis can affect a patient’s stability and neurologic function, therefore the 
two primary therapeutic targets of single dose SBRT for spinal metastases are pain control and spine 
stabilization in order to avoid cord compression (Greco et al., 2015). Deterioration of the vertebral column 
as a result of spinal metastasis is shown in Figure 1.2. SBRT is a non-invasive treatment option for 
patients unwilling to undergo surgery, with gross residual disease or deemed high risk for recurrence 
post-surgery, and for those with a poor performance status (Sahgal et al.). SBRT allows for escalation of 
tumor dose while also sparing adjacent organs at risk, particularly the spinal cord, making it an attractive 
alternative to surgery for patients with spinal metastases. Moreover, it has been reported that 86% of 
patients experienced long-term pain improvement and excellent local control with SBRT (Nalichowski et 
al., 2017). Overall, radiation therapy has primarily been used for palliative management of spinal 
metastases in patients unwilling or unfit for surgery. 
 
Figure 1.2. Axial computed tomographic view of a patient with spinal metastasis. The diseased T12 
vertebra is contoured in red. 
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1.2 Motivation for Research  
 Due to the numerous people affected by lung cancer and the challenge its location in a non-rigid 
structure presents, high levels of precision must be obtained in order to achieve a curative treatment. 
Specifically, 2-mm accuracy falls within the range of achievable setup accuracies for lung SBRT 
treatments utilizing various immobilization devices (Benedict et al., 2010; Nagata et al., 2002; Hara et al., 
2002; Wulf et al., 2000; Hof et al., 2003; Wang et al., 2006) with a 1-mm accuracy proven to be 
achievable for end-to-end localization accuracy including setup uncertainty but withholding intrafraction 
errors (Solberg et al., 2008; Verellen et al., 2003; Sharpe et al., 2006). 1-mm accuracy is generally 
recommended for spine SBRT cases considering the dosimetric effect to the spinal cord of translational 
errors greater than 1 mm (Guckenberger et al., 2007; Wang et al., 2008). Moreover, 1-mm accuracy has 
been achieved for setup with the use of stereotactic body frames (Guckenberger et al., 2007; Wang et al., 
2008; Chang et al., 2004; Yenice et al., 2003; Lohr et al., 1999) as well as end-to-end localization (Ryu et 
al., 2001; Yu et al., 2004). Additionally, with the spine as the most common site of bone metastases, their 
management poses a challenge in clinical oncology due to larger treatment volumes, numerous organs at 
risk, and lack of rigid, frame-based immobilization (Katagiri et al., 1998; Sheehan and Jagannathan, 
2008).  
 The large doses per fraction in SBRT lead to tumor ablation. However, healthy tissue cells can be 
critically damaged if they are exposed to these high levels of radiation (Papiez and Timmerman, 2008). 
Therefore, SBRT requires a high degree of accuracy. This is achieved throughout the treatment process 
with the use of immobilization devices, simulation, treatment planning, and on-board imaging. Overall, 
accurate dose delivery is dependent on correct patient positioning and physical delivery of the planned 
dose. There are uncertainties that one encounters during the treatment process; for example, 
uncertainties resulting from the imaging system used in simulation and patient positioning verification, 
mechanical uncertainties in positioning (such as the treatment couch position), and dose delivery 
uncertainties.  The latter are related to the linear accelerator output and its mechanical uncertainties in 
delivery such as gantry positioning and multi-leaf collimator positioning.  
 This research focuses on these types of uncertainties as they apply to the Elekta Infinity linear 
accelerator equipped with an Agility head, as shown in Figure 1.3, as well as the Versa HDTM linear 
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accelerator (Elekta, Stockholm, Sweden). The evaluation of these linear accelerators for their continued 
use in lung stereotactic body radiotherapy and their initial use in spinal stereotactic radiosurgery (SSRS) 
at Mary Bird Perkins Cancer Center (MBPCC) serves as the motivation for this project.  
 
Figure 1.3. Mary Bird Perkins Cancer Center Elekta Infinity linear accelerator with Agility head. MV-CBCT 
and orthogonal kV-CBCT onboard imaging pictured.  
 
1.3 Hypothesis and Specific Aims 
 The hypothesis of this work is that the Elekta Infinity and Versa HD platforms will be sufficient for 
lung SBRT and spine SRS treatments as deemed by clinical standards and metrics including percent 
difference between measured and calculated doses, positional alignment, and shifts in isodose levels that 
were designed for this project. The specific aims formulated to address the hypothesis of this work are: 
Aim 1: Generate a lung SBRT treatment plan following RTOG 0813 protocol and a spine SRS treatment 
plan following RTOG 0631 protocol. 
Aim 2:  Measure delivery accuracy through geometric and end-to-end testing. 
Sub-Aim 2a: Perform Winston-Lutz type test to assess MV isocenter accuracy. 
Sub-Aim 2b: Deliver treatment plans using a diode array phantom with 1-millimeter resolution. 
Aim 3: Evaluate delivery accuracy of the Elekta Infinity with Agility Head and Versa HD platforms.  
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Chapter 2. Methods and Materials 
2.1 Aim 1 
 To assess the delivery accuracy of the Elekta linear accelerators, treatment plans were 
developed so that their delivery could be evaluated on multiple platforms. In Aim 1, two treatment plans 
were created using the Pinnacle3 treatment planning system (Philips Radiation Oncology Systems, 
Fitchburg, WI). A 3D conformal treatment plan was generated for a lung SBRT case and a static MLC 
(sMLC) IMRT treatment plan was created for a spine SRS case.  
2.1.1 Lung SBRT Treatment Plan 
 A single patient with a right lung tumor was selected and anonymized for this study. The patient 
was previously treated with SBRT to a prescription of 50 Gy over 5 fractions using a volumetric modulate 
arc therapy (VMAT) technique. Since the goal of this study was to assess the delivery accuracy of the 
system as a whole, highly modulated or dynamically modulated plans increase complexity and introduce 
additional uncertainties attributable to the MLC model in the TPS. Therefore, a 3D conformal treatment 
plan was created to reduce TPS model uncertainties (Sutton et al., 2014). The Radiation Therapy 
Oncology Group (RTOG) Report 0813 protocol was followed to generate the treatment plan. Per the 
protocol, a 9-field 3D conformal lung stereotactic body radiotherapy plan was created consisting of seven 
static coplanar beams with the couch at 0 degrees and gantry angles of 0, 40, 135, 180, 220, 265, and 
310 degrees; and two noncoplanar beams with the couch placed at 45 degrees and gantry placed at 315 
degrees and conversely, with the couch placed at 315 degrees and gantry placed at 45 degrees (Figure 
2.1). Seven of the nine beams were planned at 6 megavoltage (MV) photon energy, with the remaining 
two beams planned at 10 MV photon energy. Two 6 MV beams were changed to 10 MV beams in order 
to minimize a few small hot spots. Gantry angles were chosen to avoid dose to normal tissue, which is of 
particular concern in SBRT cases that employ high doses per fraction. The chosen gantry beam formation 




Figure 2.1. Transaxial view of the 7-coplanar and 2-noncoplanar-beam (not pictured) treatment plan for 
the lung SBRT patient. The PTV is contoured pink in this image plane. 
 
The internal target volume (ITV), which includes the gross tumor volume (GTV) and accounts for 
respiratory motion, planning target volume (PTV), and additional contours were generated by a radiation 
oncologist. The PTV is defined by the International Committee on Radiation Units and Measurements 
(ICRU) Report 62 as the target volume necessary to account for external treatment inaccuracies including 
those resulting from patient positioning, mechanical uncertainties of the equipment, and dosimetric 
uncertainties (Wambersie, 1999). Field aperture size and shape conformed to the projection of the PTV 
along the beam’s eye view for each beam, therefore no additional margin was added to the edge of the 
blocks or MLC jaws beyond the PTV. This approach followed RTOG 0813 protocol. Beams at gantry 
angles of 40 and135° with the treatment table at 0° as well as the two non-coplanar beams at gantry 
angles of 45 and 315° with treatment table angles of 315° and 45°, respectively, were weighted 
approximately 14% due to the shorter path they traversed through normal tissue. Conversely, the 
remaining oblique beams were given approximately half this weight. The remaining beam of 265° was 
weighted approximately 12%, even though it was traversing the most amount of normal tissue, in order to 
offset those beams approaching from the contralateral side. The isocenter corresponded to the center of 
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the mass and the plan was normalized to this point by approximately 67% so that the prescription dose 
would be delivered to the margin of the PTV. In addition to the beam parameters, the dose grid resolution 
was set to 1mm when calculating the projected dose calculation. Isodose plots for the lung SBRT 
treatment plan are shown in Figure 2.2. 
 
Figure 2.2. Isodose plot of the lung SBRT treatment plan in the axial (top center), sagittal (bottom left) and 
coronal (bottom right) planes. The PTV is highlighted in red. 
 
2.1.2 SSRS Treatment Plan 
 A patient previously treated for a spine metastasis of the T-12 vertebra was anonymized for this 
study. The gross tumor volume (GTV) and clinical target volume (CTV) were contoured by a radiation 
oncologist. Per ICRU Report 62, the gross tumor volume is defined as the visible extent and location of 
the malignant growth with the CTV containing the GTV as well as an expansion for any subclinical 
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microscopic disease that is not visible by diagnostic means (Wambersie, 1999). For this treatment plan, 
the CTV was contoured to include the entire vertebral body. The GTV prescription was set to 24 Gy and 
the CTV prescription was set to 16 Gy for a single fraction. These doses were specified as objectives in 
the form of a minimum of 95% coverage in the inverse planning module of the Pinnacle treatment 
planning system. Per protocol, a treatment plan is acceptable as long as >90% of the target volume 
receives the prescribed radiosurgery dose.  A step and shoot IMRT plan was created according to RTOG 
Report 0631, since the use of IMRT could not be avoided for a plan with the target volume directly 
adjacent to the spinal cord. With the patient supine, 9 posterior 6 MV photon beams were generated with 
20 degrees of separation spanning from 260 to 100 degrees (Figure 2.3). Other objectives included 
maximum doses to the stomach, liver, kidneys, and bowel that were not to exceed their tolerance (to be 
described in Section 3.1.2) as defined by RTOG Report 0631 and MBPCC. The highest weight of the 
objectives was assigned to those pertaining to the GTV and CTV. The plan was initially optimized to 75 
iterations, with 25 iterations for the opening density matrix via pencil beam. A “warm start” of 50 iterations 
followed, and finally 30 further iterations were used to achieve a composite objective value of 0.11, which 
is satisfactory for this type of plan.  The dose grid resolution was set to 1mm. The isodose plot of the 
treatment plan is shown in Figure 2.4. Per RTOG Report 0631, the clinical target volume included the 
involved vertebral body as well as both left and right pedicles. 
 
Figure 2.3. Transaxial view of the 9-beam treatment plan for the vertebral CTV contoured in pink and the 
spinal cord (OAR) is highlighted in yellow. 
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Figure 2.4. Isodose plot of the spine SRS treatment plan in all three planes. The PTV is highlighted in 
pink and the spinal cord (OAR) is highlighted in yellow. 
 
2.1.3 Planar Dose Export 
Plans were copied to an image set of the MapCHECK2 phantom with MapPHAN in order to 
generate planar dose files which were used for comparison to delivered treatment plans. Density 
overrides of 1.05 g/cm3, 1.5027 g/cm3, and 1.6667 g/cm3 were performed to account for the MapPHAN, 
bottom section, and top section of the MapCHECK2, respectively.  The planar dose tool in Pinnacle3 
v9.10 was used to generate and export an ASCII planar dose file for each plan. The 2D coronal dose 
plane through isocenter of the spine SRS and lung SBRT plans, as well as the posterior points of 2.0 cm 
and 2.7 cm for the SSRS plan (see Section 2.2.2), were exported from the TPS 3D dose matrix for each 
treatment plan. Planar doses were calculated for a 13×13cm2 square field with a resolution of 1mm.  
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2.2 Aim 2 
 The targeting accuracy of the Elekta with an Agility head (Elekta, Stockholm, Sweden, one 
located at Mary Bird Perkins Cancer Center in Baton Rouge, Serial Number: 151892 and one located at 
the MBPCC Gonzales site, Serial Number: 151785) linear accelerator system as well as the Elekta Versa 
HDTM  linear accelerator system (located at the MBPCC Baton Rouge site, Serial Number: 153187) were 
tested through geometric testing in the form of a Winston-Lutz type test and end-to-end testing in which 
the plans from Aim 1 were delivered. Moreover, the reproducibility of the experimental set up was also 
evaluated in this aim. 
2.2.1 MV Isocenter Accuracy Test  
 In order to test the mechanical component of targeting accuracy for the Elekta linear accelerator, 
geometric testing was performed with a vendor-supplied Winston-Lutz type test (called the MV Isocenter 
Accuracy Test in this work), which followed the vendor-supplied protocol for Customer Acceptance Tests 
for MV Isocenter Accuracy. Following the stated workflow (Clements, 2016), the steps for the Winston-
Lutz test were as follows: 
1. A small high-density (typically tungsten or steel) ball bearing (BB) is placed at a location in the 
treatment room that is defined to be the mechanical isocenter point. This definition can refer to: 
coincidence of room lasers, coincidence of light-field crosshairs, or location of the tip of a front-
pointer device. Typically, the BB is placed on the treatment table such that it rotates and 
translates with the table. 
2. A small radiation field is projected through the BB onto an image receptor, such as film or 
electronic portal imaging device (EPID), using an aperture defined by MLC, primary collimator 
(jaws), or stereotactic cone. 
3. Projection images of the above are acquired for various gantry rotations and table rotations. 
Generally a total of eight images are acquired at varying gantry and couch angles in order to 
encompass the largest range of motion during a stereotactic treatment.  
4. For each projection image, the 2D deviation between the center of the BB and the center of the 
radiation field is found. 
  
For the purposes of this research, the geometric phantom consisted of the kV x-ray volume imaging (XVI) 
ball-bearing (BB) phantom (Elekta, Stockholm, Sweden) made of steel with a diameter of 8mm. The steel 
ball is located at the tip of a plastic tube that is connected to a plate, which attaches to the treatment table 
so that the BB is suspended off the table. The base plate is equipped with a set of vernier adjustments 
that allow the position of the BB to be adjusted by 0.01 mm increments. A circular collimator of 50-mm 
diameter was attached to the treatment head. The service cone was equipped with a set of micrometers 
to adjust the position of the stereotactic collimator. The gantry was set at 0° to verify the cone was 
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centered with respect to the central axis and the BB was aligned to the room crosshairs.  EPID images 
were acquired with the collimator at 0° and 180°. A 6MV energy beam was used to collect all images for 
the MV Isocenter Accuracy Test. Adjustments to the micrometers were made until there was no apparent 
movement between the images and the difference in pixel position was zero (Figure 2.5). This step 
verified that the cone alignment remained the same for varying angles, therefore the collimator was left at 
0° for subsequent image acquisitions.  
 
Figure 2.5. Comparison of the longitudinal (1) or lateral (2) edge of EPID images of the collimator 
aperture collected at collimator angles of 0° and 180° with the gantry placed at 0°. Adjustments to the 
collimator micrometers were made until the pixel value for the edge of the field were the same.  
 
 The position of the ball-bearing phantom was set by acquiring four EPID images of the phantom 
at the cardinal gantry angles using the iViewGT system (Elekta, Stockholm, Sweden). These images 
were then analyzed using commercial analysis software (RIT Isocenter Analysis Tool software V.6.3.1, 
Radiological Imagining Technology, Colorado Springs, CO) as recommended by the protocol of the 
vendor-supplied MV Isocenter Accuracy Test. The software calculated the systemic displacement on 
each principal axis using the method described in Low’s paper on minimization of target localization error 
in accelerator based radiosurgery (Low et al., 1995). Adjustments were made to the three micrometers on 
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the phantom based on the deviation results from the software analysis. Images at the four cardinal angles 
were re-acquired until the deviation between the MV isocenter and center of the ball-bearing phantom 
were less than or equal to the isocenter position tolerance of 0.1 mm. Four additional images were 
acquired with treatment table isocentric rotation angles of -90°, -45°, 45°, and 90°. The projections and 
standard deviation of the field-ball offset for each of the principal axes for were then calculated from the 
set of eight images using the analysis software.  
2.2.2 Diode Array Measurements 
 In order to test the therapeutic delivery accuracy of the Elekta linear accelerator, a two-
dimensional diode array (MapCHECK2 serial number: 76352038; Sun Nuclear Corporation, Melbourne, 
FL) was selected as the dosimeter to measure delivered dose because of its detector sensitivity. The 2D 
diode array contained 1527 diodes and an active detector area of 0.64 mm2 spanning a field size of 32.0 
× 26.0 cm. A distance of 10.0 mm separates the diodes horizontally and vertically with a spacing of 7.1 
mm diagonally.  
 As previously mentioned (Section 2.1.3), treatment plans were copied to a CT scan of the diode 
array so that calculated dose values could be compared to delivered doses for assessment of end-to-end 
testing. Due to the calibration limitations of the array, in which only one photon energy can be used for 
calibration before a measurement session, the lung SBRT treatment plan was adjusted so that the plan 
only utilized 6 MV photon beams rather than a combination of 6MV and 10MV photon beam energies. 
This enabled the correct calibration dose to be applied to the collection of one plan with the same energy 
for each beam. Calibrations were performed before each measurement session. The diode array was 
also limited in its spatial resolution, with diodes spaced 1 cm apart along the horizontal and vertical axis of 
the device. For the purposes of this project, we required a resolution of 1 mm in order to assess the 
delivery accuracy of high dose to small target volumes. To achieve 1-mm resolution, the A40 Series 
UniSlide stage (Velmex, Inc. Bloomfield, NY) was employed that allowed for incremental shifts to the 
diode array using an aluminum, vernier scale-controlled stage that moved in one direction. According to 
the manufacturer, the stage had a repeatability of 4 microns with straight-line accuracy of 0.076mm. 
Planar dose distributions of each treatment plan were measured using the diode array as shown 
in Figures 2.6, 2.7, 2.8, and 2.9. The electronic section of the diode array was centered over the moving 
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stage of the stepper motor and weighed down with steel weights so that the active detective area was 
suspended over the end of the treatment table. This configuration was used to prevent any treatment 
beams from passing through the aluminum apparatus of the electronic portion of the array. The solid 
water enclosure (MapPHAN, Sun Nuclear Corporation, Melbourne, FL) that is often used in combination 
with the diode array was not used for this study due to the additional weight it would have introduced.  
 
Figure 2.6. Patient left lateral view of x-axis (coronal right/left) shifting mechanism. 
 
 




Figure 2.8. Patient right lateral view of the setup for y-axis (coronal inferior/superior) shifting mechanism. 
 
 
Figure 2.9. Beam’s eye view for the setup for y-axis (coronal inferior/superior) shifting mechanism. 
 
All measurements of the lung SBRT and spine SRS plans were taken in the coronal plane. For 
those deliveries in which the diode array was positioned at isocenter, shifts were made along the x-axis 
and y-axis, defined as patient left and patient right; and patient superior and inferior, respectively. These 
measurements are referred to as coronal left/right and coronal superior/inferior in this work. In addition to 
the plane through the isocenter for the SSRS case, two supplementary coronal planes were evaluated in 
the posterior direction of the patient (i.e. the diode array was shifted vertically down). These additional 
positions represent the coronal plane along the z-axis for the SSRS case. Since the array orientation was 
in the coronal plane, shifts along the x-axis using the aluminum stage were performed in order to assess 
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the dose delivery to the steepest dose gradients in the plan. These areas are characterized by the 
horseshoe shape isodose lines encompassing the vertebral column and excluding the spinal cord so that 
dose can be limited to the spinal cord. One of the coronal posterior positions was taken at 2 cm and the 
other at 2.7 cm (Figure 2.10). These points were chosen to represent the coronal plane approximately 
through the juncture of the vertebral PTV and spinal cord contour (a high dose gradient region) and the 
coronal plane directly through the spinal cord and adjacent vertebral pedicles, respectively (Figures 2.11 
and 2.12).   
            
Figure 2.10. SSRS plan with 2cm and 2.7cm distance measured from CTV isocenter displayed in the 
axial plane with corresponding sagittal (bottom left) and coronal (bottom right) planes displayed. The CTV 
is outlined in red and the OAR (spinal cord) is contoured in yellow. 
 
 
Figure 2.11. SSRS coronal plane of 2 cm posterior shift from CTV isocenter. The OAR (spinal cord) is 
contoured in yellow with the 16 Gy isodose line targeting the CTV outlined in blue and the 24 Gy isodose 
line targeting the GTV in green. 
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Figure 2.12. SSRS coronal plane of 2.7 cm posterior shift from CTV isocenter. The OAR (spinal cord) is 
contoured in yellow with the 16 Gy isodose line targeting the CTV outlined in blue and the 24 Gy isodose 
line targeting the GTV in green. 
 
2.2.3 Diode Array Positioning with kV-CBCT 
These additional vertically positioned measurements were also designed to test the IGRT 
capabilities of the Elekta Infinity platform. For those measurements of the lung SBRT and spine SRS plan 
taken through the isocentric coronal plane, the diode array was aligned using the room lasers so that the 
plane of diodes was parallel to the coronal plane of a supine patient. Rather than moving the treatment 
table to the desired posterior offset for the spine SRS plan by referencing the monitor readouts with 0.1 
cm precision, IGRT capabilities provided images before and after posterior positioning that allowed for 
comparison and confirmation of the applied alignment with 0.01 cm precision. To position the 
MapCHECK2 to its specified positions of 2 cm and 2.7 cm posteriorly, a kilovoltage cone beam computed 
tomography (kV-CBCT) image was taken using the x-ray volume imaging system (XVI) to align the diode 
array position with that in the planning CT data set of the phantom exported from the TPS.  Each kV-
CBCT was acquired using the “S20 Head and Neck” MBPCC protocol where a cone-beam is taken 
without a filter (F0) using a small collimator field of view with an axial length of 26 cm (S20). The protocol 
uses a small field-of-view, kV tube potential of 100kV, and current of 10 mA. Once the kV-CBCT was 
acquired, it was automatically registered to the reference CT image set using grey-scale matching (Figure 
2.13). A clipbox was set to only include the central diodes of the array so as to avoid any misalignment 
due to image artifacts from the outer edges of the kV-CBCT. However, the perimeter of the diode array, 
as seen in the coronal image window in Figure 2.13 and 2.14, was used to confirm that the row alignment 
of the diodes was correct. The registration was visually evaluated using a dual-image system that 
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overlays the images. After the diode array was aligned to the reference image, the table was then 
positioned the calculated amount and a kV-CBCT was re-acquired in order to ensure the adjusted 
position was within ±0.05 cm of what was expected (Figure 2.14). For the spine SRS treatment plan only, 
the posterior offset was achieved once the Elekta Infinity software automatically translated the treatment 
table by the specified amounts. The SSRS plan was then delivered to the diode array after the desired 
posterior position was achieved.  
 
Figure 2.13. Screenshot of XVI 3D-kVCBCT registration window. The kVCBCT was aligned to the 
planning CT at isocenter in this figure. (Cross sections represent the overlaid intersection of the acquired 
CBCT, shown here as the lighter contrasted image, and the Pinnacle Export reference image, shown 
here as the darker contrasted image). 
 
 
Figure 2.14. Screenshot of XVI 3D-kVCBCT registration window. The kVCBCT was aligned to the 
planning CT at isocenter in this figure after a 2cm posterior shift. (Cross sections represent the overlaid 
intersection of the acquired CBCT, shown here as the lighter contrasted image, and the Pinnacle Export 
reference image, shown here as the darker contrasted image). 
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2.2.4 Concatenation of Measurements  
An in-house MATLAB (MathWorks Inc., Natick, Massachusetts) code was developed to 
concatenate the 1-mm shifted data into one file to be analyzed by the commercial software that supports 
the diode array (SNC Patient TM software, version 6.2.2, Sun Nuclear Corporation, Melbourne, FL). The 
aggregate data file was then analyzed along the axis in which the diode array was shifted. For example, 
the typical data dimensions for a diode array text file are 65 × 53, which corresponds to the number of 
diodes in each direction with 1-cm spacing along vertical and horizontal axes. With the 1-mm shift applied 
in one direction along one of the axes in 2-D space, the number of columns expanded to 270 for the 
coronal left/right shift and the number of rows expanded to 330 for the superior/inferior shift. This 
represents the initial position of the diodes with an additional 9 data points to fill in the 1-cm gap between 
diodes along a given axis.   
2.2.5 Reproducibility 
 Measurement sessions occurred on separate days and therefore required repeated construction 
of the experimental setup; therefore, assuring reproducibility in setup was crucial to the developed design. 
Measurements taken through isocenter for the lung SBRT and SSRS plans were replicated for shifts 
along the coronal left/right axis and the coronal superior/inferior axis. For the posteriorly positioned 2.0 cm 
and 2.7 cm SSRS plan deliveries, shifts in the diode array were only applied along the coronal left/right 
axis. Reproducibility was only assessed using the aggregate data files of the coronal left/right axis for the 
posteriorly positioned SSRS plans. Experimental reproducibility was assessed by overlaying the 
aggregate measured dose distributions for a given shift within the coronal plane and calculating the 
positional alignment error and shift in isodose levels, which are described in the following section.  
2.3  Aim 3 
 Delivery accuracy was quantified using three analysis metrics: percent difference between 
measured and planned dose values, positioning alignment, and difference in isodose levels. After the 
measurements were analyzed, additional tests were required to explain the results from the delivery of 
the treatment plans.  
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2.3.1 Analysis Metrics 
Percent Difference 
 Due to a noticeable dose discrepancy in the center of the SSRS profile between the measured 
dose delivery and that generated by the treatment planning system, the percent difference between the 
measured and planned value for the center point in the MapCHECK2 array was calculated using the 
standard formula:  
 
% 𝐃𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐜𝐞 =  
(𝐦𝐞𝐚𝐬𝐮𝐫𝐞𝐝 𝐝𝐨𝐬𝐞 𝐯𝐚𝐥𝐮𝐞 − 𝐩𝐥𝐚𝐧𝐧𝐞𝐝 𝐝𝐨𝐬𝐞 𝐯𝐚𝐥𝐮𝐞)
𝐩𝐥𝐚𝐧𝐧𝐞𝐝 𝐝𝐨𝐬𝐞 𝐯𝐚𝐥𝐮𝐞
 × 𝟏𝟎𝟎 (1) 
The percent difference of the measured and planned center point dose value was only calculated for the 
SSRS coronal left/right plane with a 2 cm and 2.7 cm posterior shift. The center point in these planes 
represents the approximate location of the spinal cord in the plan, specifically where it abuts to the 
vertebral column (2cm profile) and the center of the spinal cord (2.7 cm profile). Percent difference was 
calculated for this point, in particular, due to the strict dose tolerance of the spinal cord and the potential 
for large overdoses due to inaccurate treatment delivery. Percent difference between measured and 
calculated dose points was not calculated for the deliveries of the lung SBRT or spine SRS plans through 
the coronal plane at isocenter. 
Positional Alignment Error 
 The positional alignment error (Δc) for those measurements taken at isocenter with no posterior 
shift applied was defined as the displacement between the center of the planned and measured profiles 
(defined as the midpoint between the 75% dose levels on each side of the profile): 
 Δc = ½ (X75%,TPS+ + X75%,TPS-) – ½ (X75%,Meas+ + X75%,Meas-) (2) 
Where X75% refers to the position of the 75% maximum dose point as calculated by the TPS and 
subscripts (+) and (-) refer to the slopes of the profile while moving across the profile from patient left to 
patient right or patient inferior to patient superior respectively. The 75% dose value was selected as it is 
located near the point of steepest dose gradient. Because 100% dose refers to an absolute maximum 
dose of 2046 cGy as calculated by the TPS for the lung SBRT plan transferred to the diode array 
phantom, the 75% dose correspond to an absolute dose of 1535 cGy. Similarly, the 100% dose refers to 
an absolute maximum dose of 3784 cGy as calculated by the TPS for the spine SRS plan, which makes 
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the 75% dose corresponds to 2838 cGy. The 75% dose point was used to calculate the positional 
alignment error those profiles taken along the patient left-right axis and the patient superior-inferior axis 
for the lung SBRT and spine SRS treatment delivery profiles of the coronal plane taken through isocenter. 
 The positional alignment error (Δc) for the SSRS measurements taken at additional posterior 
alignments of 2cm and 2.7cm was defined as the displacement between the center of the planned and 
measured profiles (defined as the midpoint between the 60% dose levels on each outer side of the 
profile):  
 Δc = ½ (X60%,TPS+ + X60%,TPS-) – ½ (X60%,Meas+ + X60%,Meas-) 
 
(3) 
Where X60% refers to the position of the 60% maximum dose point as calculated by the TPS and 
subscripts (+) and (-) refer to the slopes of the profile while moving across it from patient left to patient 
right respectively. The 60% maximum dose point was used for the posteriorly offset SSRS profiles 
because the 75% maximum dose point was not applicable for one or more profiles as they did not receive 
this dose during delivery due to the high dose gradient across profiles. Rather, a lower percentage of the 
maximum dose point was chosen because it similarly corresponds to the approximate point of the 
sharpest dose gradient as the 60% maximum dose value corresponds to 2270 cGy of the SSRS absolute 
maximum dose. Positional alignment error was only calculated for the patient left-right axis for the 
posteriorly offset SSRS treatment delivery, as shifts in the diode array were not made along the patient 
superior-inferior axis. 
Overall, the value of Δc is a degree of the alignment error in a measurement, where positive 
values indicate a shift of the measured profile in the left or inferior direction and negative values indicate a 
shift in the right or superior direction relative to the planned profile (Sutton et al., 2014).  
Difference in the 75% and 60% Dose Levels 
 Shifts in the 75% dose level (Δ75) represented the asymmetric deviations in the 75% isodose 
lines within the profiles of the coronal plane of delivered lung SBRT and SSRS plans taken through 
isocenter. Moreover, the shift in dose point served as an evaluation of coverage of the tumor volume. The 
75% dose level shifts were defined as: 
 Δ75Right = 75%TPS,R – 75%Meas,R (4) 
 Δ75Left = 75%Meas,L – 75%TPS,L (5) 
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 Δ75Superior = 75%TPS,S – 75%Meas,S (6) 
 Δ75Inferior = 75%Meas,I – 75%TPS,I (7) 
 
Where the subscripts R, L, S, and I denote the right, left, superior, and inferior sides of the profile, 
respectively. Positive values of Δ75 indicated that the position of the measured 75% isodose fell inside 
the calculated (planned) 75% isodose line. Conversely, negative values of Δ75 indicated that the 
measured 75% isodose line fell outside the calculated (planned) 75% isodose line.  
 Differences in the 60% isodose levels (Δ60) represented the asymmetric deviation and the 
coverage of the target volume in the 60% isodose lines within the profiles of the delivered SSRS plan 
posteriorly offset by 2cm and 2.7cm. Shifts in the 60% dose level  were defined as: 
 Δ60Right = 60%TPS,R – 60%Meas,R (8) 
 Δ60Left = 60%Meas,L – 60%TPS,L (9) 
 
With the same defining characteristics as Δ75. Of note, Δ60Superior and Δ60Inferior  were not calculated for 
the posteriorly aligned diode array for the delivery of the SSRS treatment plan because shifts were made 
only along the patient left-right axis.  
 A sample profile has been provided that demonstrates the metrics previously described, including 
the positional alignment error and the difference in isodose levels (Figure 2.15). For the chosen profile, 
Figure 2.15 displays Δ75 for one of the lung SBRT treatment plan deliveries.  
 
Figure 2.15. Sample profile illustrating the positional alignment error and difference in75% isodose level 
metrics on a profile of the delivered and calculated lung SBRT treatment. 
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2.3.2 Delivery of Treatment Plans on Additional Linear Accelerators 
 Additional measurements were collected across three linear accelerators to test for differences 
between the delivery capabilities and performance of each unit. Using the same methods previously 
described (Section 2.2.2), the lung SBRT treatment plan and the SSRS treatment plan offset posteriorly 
by 2.0 cm and 2.7 cm were delivered on two additional linear accelerators: the Elekta Versa HDTM linear 
accelerator and an additional Elekta InfinityTM  with Agility head linear accelerator. Measurement sessions 
utilized the XVI system to acquire kV-CBCT images to aid in positioning the MapCHECK2 diode array 
(Section 2.2.3).  
2.3.3 Individual Gantry Beam Measurements 
 To further assess the dose discrepancy in treatment delivery of the spine SRS plan, each 
treatment field was delivered at the prescribed gantry angle as well as at 0° to the MapCHECK2 with 
MapPHAN for the 2.0 cm and 2.7 cm posteriorly shifted measurement sessions. The planar dose for each 
beam with the corresponding posterior offset of either 2.0 or 2.7 cm was generated with the same method 
as described in section 2.1.3. Additionally, to isolate the planar dose for each beam at its planned gantry 
and collimator angle, the number of monitor units was set to zero for all beams but one before exporting 
the file. For the delivery of the beams at gantry and collimator angle 0, the orientation of the beams were 
manually modified while leaving the MLC control points the same, which resulted in the delivery of the 
same number of monitor units and MLC leaf configuration for each beam.  
 Individual beam measurements were taken with the diode array posteriorly offset by 2.0 and 2.7 
cm and the fields delivered at their planned angle. An additional measurement consisted of the treatment 
beams delivered at 0° for the gantry and collimator angles. By delivering the beams at gantry angle 0° 
and collimator angle 0°, the potential for over-response from the diodes resulting from oblique gantry 
angles was minimized. Analysis of the data was performed using the aforementioned percent difference 
formula for the center point of the measured and calculated treatment plan.  
2.3.4 Ion Chamber Measurements 
 Because diodes have been reported to exhibit directional dependence (Jursinic, 2009; Keeling et 
al., 2013; Jursinic et al., 2010), additional measurements were required to determine the cause of a 
specific discrepancy between the TPS calculated dose and the measured dose to the (0,0) point in the 
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SSRS plan with an applied posterior offset of 2 cm and 2.7 cm. To establish whether the measured dose 
at this point was actually being delivered or the potential result of over-responding diodes, the absolute 
dose was measured with an Exradin A1SL ion chamber (Standard Imaging, Inc., Middleton,WI; SN: 
XW120896) inserted in a cylindrical, solid water “cheese” phantom with radius of 15 cm and a width of 18 
cm (Accuray, Inc. TomoTherapy©, Sunnyvale, CA). Measurement readings were recorded from the 
CNMC Instruments Inc. Model 206 Dosimetry Electrometer. The SSRS treatment plan was copied to an 
image set of the “cheese” phantom, and the dose to the approximate active detector volume of the A1SL 
ion chamber located 2 cm and 2.7 cm posterior to the isocenter point was calculated for each treatment 
beam using the TPS. The volume of the A1SL ion chamber is 0.053 cm3 and the volume contoured was 
0.063 cm3; the exact volume of the chamber could not be contoured since the CT slice is 2.5 mm, 
therefore limiting the range of volume that could be contoured. The ion chamber was then placed in the 2-
cm posterior insert within the phantom and three measurements for each beam were acquired and 
averaged for dose calculations (Figure 2.25). Since no insert exists for a 2.7 cm shift, the table was 
shifted down by 0.7 cm for this additional measurement. Using an adaptation of the TG-51 formalism 
(Almond et al., 1999) to determine the photon dose, the absorbed dose to water was calculated and 
converted to absorbed dose for muscle using the formula below:  
 






Where 𝑀!"# represents the uncorrected ion chamber reading, 𝑃!"# is the recombination correction factor 
that takes into account the incomplete collection of charge from an ion chamber, 𝑃!" is the temperature-
pressure correction factor which makes the charge correspond to the standard environmental conditions 
for which the calibration factor applies, 𝑃!"!# represents the electrometer correction factor, and 𝑃!"# is the 
polarity correction factor which takes into account any polarity effect in the response of the ion chamber. 
Additionally, 𝑘! is the quality conversion factor that accounts for the change in the absorbed-dose to 
water calibration factor between the beam quality of interest, Q, and the beam quality of Co-60 for which 
the absorbed-dose calibration factor applies. 𝑁!,!!"!!" represents the absorbed-dose to water calibration 
factor for an ion chamber located under reference conditions in a radiation beam of Co-60 beam quality. 
Since dose to muscle is the quantity of interest in clinical dosimetry, absorbed dose to water must be 
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converted to absorbed dose to muscle in order to compare those values generated by the TPS to what 
was measured. The mass energy absorption coefficient ratio between muscle and water, (!
!
)!"#$%!"#$%&, was 
used to convert the absorbed dose in water to the absorbed dose in muscle.  
 




Chapter 3. Results  
3.1 Results of Treatment Planning 
3.1.1 Lung SBRT Treatment Plan 
The lung SBRT treatment plan was designed to follow dose constraints outlined by RTOG Report 
0813, which can be found in Table 3.1. Specifically, the maximum dose of the treatment plan requires that 
100% corresponds to the maximum dose delivered to the patient that must occur within the PTV. The 
prescription isodose surface had to be ≥60% and ≤90% of the maximum dose.  The prescription isodose 
surface coverage constraint requires at least 95% of the PTV receive the prescription dose (V100 ≥ 95%) 
and that 99% of the PTV receive a minimum of 90% of the prescription dose dose (V90 ≥ 99%). Lastly, the 
constraint for high dose spillage limited the volume of tissue outside the PTV to be no greater than 15% of 
the PTV volume that received a dose >105% of the prescription dose.  
Table 3.1: RTOG 0813 Protocol Requirements 
Criteria Constraint 
Maximum Dose 100% corresponds to the maximum dose 
delivered to the patient; point must exist within 
the PTV 
Prescription Isodose ≥60% and ≤90% 
Prescription Isodose Surface Coverage PTV V100 = 95% and PTV V90 > 99% 
High Dose Spillage Cumulative volume of all tissue outside the PTV 
receiving >105% of prescription dose ≤ 15% of 
the PTV volume 
 
Additionally, the generated lung SBRT treatment plan also met the requirements for conformality 
of prescribed dose described subsequently. With a PTV of 57.45 cm3, the RTOG 0813 requirements were 
met (Figure 3.1). Specifically, the ratio of prescription isodose volume to the PTV volume did not exceed 
the ratio requirement of 1.5 for the PTV volume. Also, the ratio of 50% prescription isodose volume to the 
PTV volume (R50%) and maximum dose in percent of dose prescribed at 2 cm from PTV in any direction 
[D2cm (%)] did not exceed the requirements as listed in RTOG Report 0813. With all constraints and 
requirements met, the lung SBRT treatment plan met all stated RTOG requirements.  
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Figure 3.1. Scorecard containing objectives for the lung SBRT plan. 
 
3.1.2 SSRS Treatment Plan 
The SSRS treatment plan met the protocol requirements of RTOG Report 0631 as shown in 
Table 3.2. Figure 3.2 displays the scorecard from the treatment planning system. Of note, the maximum 
dose to the spinal cord was 1011.2 cGy, which was well below the maximum dose constraint of 1400 
cGy. Moreover, the treatment plan design achieved a prescribed dose of 16 Gy in one fraction to cover at 
least 90% of the CTV as well as 90% coverage to the GTV that received 24 Gy.  Since all goals and 
constraints were met, the SSRS treatment plan was considered clinically acceptable and used for end-to-
end testing to assess the delivery accuracy of multiple Elekta linear accelerators.  
Table 3.2. RTOG 0631 Protocol Requirements and MBPCC Constraints 
Organ at Risk (OAR) Constraint 
Spinal Cord Max Dose ≤ 14 Gy 
Spinal Cord 12 Gy to less than 0.01cc 
Kidney Max Dose of 10 Gy 
Liver Max Dose of 10 Gy 
Stomach Max Dose of 11 Gy 





Figure 3.2. Scorecard containing objectives for the spine SRS plan. 
 
3.2 MV Isocenter Accuracy Test Results 
 Table 3.3 contains the results of the MV Isocenter Accuracy test for the three linear accelerators 
used for this study. Infinity 1 refers to the Elekta Infinity™ with Agility head located at the MBPCC Baton 
Rouge site. Versa HD refers to the Elekta Versa HD™ linear accelerator, also located at the MBPCC 
Baton Rouge site. Moreover, Infinity 2 refers to the additional Elekta Infinity™ with Agility head linear 
accelerator located at the MBPCC Gonzales site. Per the 6 MV Isocenter Customer Acceptance protocol, 
MV isocenter radius for gantry rotation has a limit of ≤ 0.70 mm. Additionally, the limit of the MV isocenter 
radius for the combined gantry and treatment table rotation is ≤1.00 mm. For the Infinity 1 and Versa HD 
linear accelerators, the maximum MV isocenter radius for both the gantry and treatment table rotation 
was a result of the gantry rotation, which is why the radius for gantry rotation and combined gantry and 
treatment table rotation are the same. Since the results of the MV isocenter accuracy test was within 
tolerance for the MV isocenter radius for the combined gantry and treatment table rotation and only a 
maximum of 0.01 mm from being within tolerance for the gantry rotation for all three linear accelerators, 
no adjustments were made to the mechanical aspects of the delivery system to improve the radius of 
isocenter.  
Table 3.3. Results of the MV Isocenter Accuracy Test for three linear accelerators. 
Linear Accelerator MV Isocenter Radius for Gantry Rotation (mm) 
MV Isocenter Radius for 
Combine Gantry and 
Treatment Table Rotation (mm) 
Infinity 1 0.71 0.71 
Versa HD 0.69 0.69 




3.3 Results of Treatment Deliveries  
3.3.1 Reproducibility of Diode Array Setup 
 The reproducibility of the experimental setup was evaluated by overlaying repeated delivered 
treatment plans that were shifted in the same direction. Table 3.4 contains the average positional 
alignment error between two measured trials of the treatment delivery of the lung SBRT and spine SRS 
plan. Equations 2 and 3 were used to calculate the positional alignment (Δc) between the two measured 
profiles, where the midpoint value for the TPS-calculated value was replaced with the midpoint value from 
trial 1 and the midpoint value of trial 2 was subtracted. Positive Δc values indicated a left or inferior shift of 
trial 2 relative to trial 1. Tables 3.5 and 3.6 display values for the shift in 75% isodose levels between 
measured deliveries. Equations 4-7 were used to calculate the difference in isodose levels. Δ75Right and 
Δ75Superior were calculated by subtracting the 75% dose level position of trial 2 from the 75% isodose level 
position of trial 1. Δ75Left and Δ75Inferior were calculated by subtracting the 75% isodose level position of 
trial 1 from that of trial 2. Similarly, the values for Δ60 in Table 3.7 were calculated in the same manner for 
those profiles that were posteriorly offset. Positive Δ75 and Δ60 values indicate that the profile of trial 2 
fell within the profile of trial 1. Conversely, negative Δ75 and Δ60 values indicate that the profile for trial 2 
fell outside that of trial 1. Ideally, positional alignment and shifts in the isodose levels would be zero if 
there were no uncertainties within the setup. However, the values from Tables 3.4 - 3.7 indicate that the 
uncertainty in the reproducibility of the setup was less than 1mm on average. Figures 3.3 - 3.8 display 
sample overlaid profiles taken through the central axis of the measured deliveries. Overall, the precision 
of repeated measurements of the same plan with device setup re-constructed for each session was 













Table 3.4. Average positional alignment comparison between two measured treatment delivery trials 
demonstrating reproducibility of setup for treatment deliveries on the Elekta Infinity linear accelerator with 
Agility head. Positive values of Δc indicate a left or inferior shift of trial 2 relative to trial 1. Conversely, 
negative values of Δc indicate a right or superior shift of trial 2 relative to trial 1. 







Lung SBRT Left-Right 0.13 0.08 0.17 
Lung SBRT Superior-Inferior -0.13 -0.24 -0.04 
SSRS Left-Right 0.08 -0.03 0.15 
SSRS Superior-Inferior -0.21  -0.62 -0.07 
SSRS, 2 cm Left-Right -0.61 -0.69 -0.55 
SSRS, 2.7 cm Left-Right -0.16 -2.46 0.56 
 
Table 3.5. Average shift in 75% isodose level comparison between two measured treatment delivery trials 
demonstrating reproducibility of setup for treatment deliveries on the Elekta Infinity linear accelerator with 
Agility head. Values are for profiles of 1-mm resolution along the patient left-right axis, where a positive 
Δ75Left or Δ75Right indicates the trial 2 isodose level fell within the trial 1 profile. Conversely, a negative 






















SBRT -0.14 -0.30 -0.01 0.12 -0.03 0.32 
SSRS -0.04 -0.16 0.13 0.12 0.05 0.20 
 
Table 3.6. Average shift in 75% isodose level comparison between two measured treatment delivery trials 
demonstrating reproducibility of setup for treatment deliveries on the Elekta Infinity linear accelerator with 
Agility head. Values are for profiles of 1-mm resolution along the patient superior-inferior axis, where a 
positive Δ75Inferior or Δ75Superior indicates the trial 2 isodose level fell within the trial 1 profile. Conversely, a 






















SBRT 0.05 -0.06 0.12 -0.24 -0.37 -0.13 
SSRS 0.29 0.05 0.71 -0.13 -0.53 0.07 
 
Table 3.7. Average shift in 60% isodose level comparison between two measured treatment delivery trials 
with posterior offsets demonstrating reproducibility of setup for treatment deliveries on the Elekta Infinity 
linear accelerator with Agility head. Values are for profiles of 1-mm resolution along the patient left-right 
axis, where a positive Δ60Left or Δ60Right indicates the trial 2 isodose level fell within the trial 1 profile. 






















2cm 0.40 0.26 0.49 -0.82 -0.89 -0.73 
SSRS, 




Figure 3.3. Profiles of repeated measurements for the lung SBRT plan in the coronal plane taken at 0 cm 
along the superior-inferior axis; used for determining reproducibility of the experimental setup.  
 
 
Figure 3.4. Profiles of repeated measurements for the lung SBRT plan in the coronal plane taken at 0 cm 
along the left-right axis; used for determining reproducibility of the experimental setup.  
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Figure 3.5. Profiles of repeated measurements for the spine SRS plan in the coronal plane taken at 0 cm 
along the superior-inferior axis; used for determining reproducibility of the experimental setup. 
 
Figure 3.6. Profiles of repeated measurements for the spine SRS plan in the coronal plane taken at 0 cm 
along the left-right axis; used for determining reproducibility of the experimental setup. 
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Figure 3.7. Profiles of repeated measurements for the spine SRS plan posteriorly offset by 2 cm in the 




Figure 3.8. Profiles of repeated measurements for the spine SRS plan posteriorly offset by 2.7 cm in the 
coronal plane taken at 0 cm along the superior-inferior axis; used for determining reproducibility of the 
experimental setup. 
Position (mm)








































 An example profile taken from Appendix A has been included to illustrate a feature that resulted 
from the aggregate file of the combined 1-mm shifts of the diode array.  Shown in Figure 3.9 is a profile 
from the delivery of the lung SBRT treatment plan on the Elekta Infinity linear accelerator taken through 
the superior-inferior point of 0.5cm (Y = 0.5cm). Figure 3.9 (A) is an analysis performed by the SNC 
Patient Software of one of the nine individual files that were combined to form the aggregate data file with 
1-mm resolution along a single axis, Figure 3.9 (B). The diode within the green circle (A) measured a 
higher dose than the diodes directly adjacent to it. When the individual files were combined to form the 
aggregate this resulted in an artifact resembling a plateau that is highlighted with the green circle in 
Figure 3.9 (B). These characteristics are found in several of the measured profiles that were used for 
analysis in this research. The data points in Figure 3.9 (A) represent distinct measured diode doses that 
when they were combined created a smearing effect seen in Figure 3.9 (B). 
 
Figure 3.9. (A) SNC Patient Software profile of a single delivery of the lung SBRT plan analyzed at the 
native resolution of the diode array. (B) Sample plotted profile of the aggregate data file for 9 sequential 
deliveries of the lung SBRT plan, including that of (A). 
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3.3.2 Analysis of Treatment Delivery 
 Figures 3.10, 3.11, and 3.12 are comparisons between the calculated and delivered treatment 
plans created in Aim 1 and delivered with the methods described for Aim 2. Specifically, Figure 3.10 
shows lung SBRT profiles taken through Y = 0 cm for three linear accelerators as well as the calculated 
profile from the TPS. Measurement sessions for the delivery of the lung SBRT plan did not utilize kV-
CBCT imaging for setup. Overall, agreement between the planned and delivered lung plan profiles was 
similar across all linear accelerators. Quantitative comparisons follow in the subsequent sections.  
 
Figure 3.10. Comparison of profiles the planned and delivered lung SBRT treatment plan on three linear 
accelerators; profiles were taken through Y = 0cm on superior-inferior axis.  
 
Conversely, the agreement across linear accelerators for the delivery of the SSRS plan varied, as 
seen in Figures 3.11 and 3.12. Both measurement sessions for the posteriorly offset diode array for the 
SSRS delivery utilized kV-CBCT imaging for experimental setup. Figure 3.11 displays the overlaid profiles 
taken through Y = 0 cm for the three linear accelerators as well as the calculated TPS profile for the 
SSRS treatment plan through the 2-cm posterior coronal plane. Upon visual inspection, large 
discrepancies can be seen at the center of the profile, which represents the area where the spinal cord is 
adjacent to the vertebral column. As previously stated, this profile falls within a high dose gradient region 
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so variability was expected due to the fact that a sub-millimeter misalignment in the anterior-posterior 
direction could result in a drastically different dose. However, the degree of variability (see Table 3.8) that 
resulted from the treatment deliveries led to further analysis described in the following sections. Similar 
results can be seen in Figure 3.12 that displays the overlaid profiles taken through Y = 0 cm for the 
calculated and delivered SSRS treatment plan through the 2.7-cm posterior coronal plane. A similar dose 
discrepancy between planned and calculated values at the center of the profile for the 2.7 cm posterior 
offset coronal plane (representing the region of the spinal cord) can be seen in Figure 3.12.  
  
Figure 3.11. Comparison of the center profiles of the planned and delivered spine SRS treatment plan 
posteriorly shifted by 2 cm on three linear accelerators profiles; were taken through Y = 0 cm on superior-
inferior axis.  
Percent Difference 
 Table 3.8 shows the percent difference calculated for the central diode of the delivered SSRS 
treatment plans shifted posteriorly by 2 cm and 2.7 cm as compared to the planned dose for the central 
diode on the TPS-generated planar dose. As previously stated, the central diode was chosen in the 
coronal left-right profile to represent the approximate position of the junction of the spinal cord and 
vertebral column, at the 2 cm profile, and the center of the spinal cord, at the 2.7 cm profile. The 
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measured dose at the center point of the profile was consistently higher than that which was planned, 
suggesting a systematic difference between measurement and calculation. 
  
Figure 3.12. Comparison of the center profiles of the planned and delivered spine SRS treatment plan 
posteriorly shifted by 2.7 cm on three linear accelerators; profiles were taken through Y = 0 cm on 
superior-inferior axis.  
 
Table 3.8. Percent Difference between TPS calculated dose and delivery of the treatment plan measured 
dose at the central point of the MapCHECK2 diode array. All measurements were taken in the coronal 
















Infinity 1 1 2.0 1198.2 960.5 24.75% 
Infinity 1 2 2.0 1168.7 960.5 21.67% 
Versa HD 1 2.0 1339.0 960.5 39.41% 
Infinity 2 1 2.0 1112.2 960.5 15.79% 
Infinity 1 1 2.7 592.6 485.3 29.32% 
Infinity 1 2 2.7 585.6 485.3 27.78% 
Versa HD 1 2.7 622.4 485.3 35.83% 
Infinity 2 1 2.7 535.3 485.3 16.81% 
 
Positional Alignment Error  
 
Table 3.9 contains the data corresponding to the average positional alignment error (Δc) between 
the measured and planned lung SBRT and SSRS profiles taken through Y = 0, -0.5, -1, 0.5, and 1 cm for 
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the left-right direction and X = 0, -0.5, -1, 0.5, and 1 cm for the superior-inferior direction (see Appendix 
A). The range, displayed as minimum and maximum values, was also calculated. The meanings of 
positive and negative values of Δc were described in Section 2.3.1. 2-mm accuracy has been achieved 
for lung SBRT treatment delivery with a 1-mm accuracy achieved for spine SRS treatments (see Section 
1.2), therefore these values served as the standard for the positional alignment error of the delivered 
treatment plans. Ideally, all data points would align on the central axis specific to the direction of the 
increased resolution. For example, those measurements with 1-mm resolution in the left-right direction 
would ideally have a positional alignment error of zero along the y-axis and vice versa for those 
measurements with 1-mm resolution in the superior-inferior direction. Overall, average positional 
alignment indicated a shift of the measured profile in the left or inferior direction due to the primarily 
positive values.  
Table 3.9. Summary of Δc analysis metric for the delivery of the lung SBRT and SSRS treatment plans 
delivered on three linear accelerators. Positive values of Δc indicate a shift of the measured profile in the 
left or inferior direction relative to the planned profile. Negative values of Δc indicate a shift in the right or 













Infinity 1 Lung SBRT Left-Right 0.3 -0.1 1.2 
Infinity 1 Lung SBRT Superior-Inferior 0.2  -0.7 0.6 
Versa HD Lung SBRT Left-Right 0.5  0.0 1.6 
Infinity 2 Lung SBRT Left-Right 0.4  0.0 1.0 
Infinity 1 SSRS Left-Right -0.1  -0.5 0.4 
Infinity 1 SSRS Superior-Inferior 0.4  -0.5 1.3 
Infinity 1 SSRS, 2 cm Left-Right 0.5  -0.2 1.3 
Versa HD SSRS, 2 cm Left-Right 0.2  -0.3 0.8 
Infinity 2 SSRS, 2 cm Left-Right 0.0  -0.4 0.4 
Infinity 1 SSRS, 2.7 cm Left-Right 0.6  -0.8 1.7 
Versa HD SSRS, 2.7 cm Left-Right 0.4  -0.4 1.1 
Infinity 2 SSRS, 2.7 cm Left-Right -0.6  -1.9 0.2 
 
Shift in 75% and 60% Isodose Level  
 Table 3.10 and 3.11 show the average values of the shifts in the 75% dose points (Δ75) for the 
profiles of the delivered lung SBRT and SSRS plans with isocentric setup.  Profiles were taken through Y 
= 0, -0.5, -1, 0.5, and 1 cm for the evaluation of Δ75Left and Δ75Right with profiles taken through X = 0, -0.5, 
-1, 0.5, and 1 cm for the evaluation of Δ75Superior and  Δ75Inferior (see Appendix A). Specifically, Table 3.10 
displays the values for Δ75Left and Δ75Right  as well as the minimum and maximum of calculated values 
corresponding to the measurements with a resolution of 1 mm in the left-right direction, while Table 3.11 
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contains values for Δ75Superior and  Δ75Inferior  as well as the minimum and maximum values, which 
correspond to the measurements with a resolution of 1 mm in the superior-inferior direction. The values of 
Δ75 represent the asymmetric deviations in the 75% isodose lines between the measured and planned 
profiles (Section 2.3.1). 
Table 3.10. Δ75Left and Δ75Right  for lung SBRT and spine SRS profiles on three linear accelerators. 
Positive values of Δ75Left and Δ75Right  indicated that the position of the measured 75% isodose line fell 
inside the planned 75% isodose line. Negative values of 75Left and Δ75Right  indicated that the measured 























Infinity 1 Lung SBRT -1.2 -2.1 -0.4 -0.5 -1.4 0.4 
Versa HD Lung SBRT -0.8 -1.9 0.4 0.2 -0.7 1.3 
Infinity 2 Lung SBRT -0.2 -0.6 0.1 0.6 0.2 1.5 
Infinity 1 Spine  SRS -0.7 -1.7 0.2 -0.8 -1.3 -0.3 
 
Table 3.11. Δ75Superior and  Δ75Inferior for lung SBRT and spine SRS profiles on an Elekta Infinity linear 
accelerator. Positive values of Δ75Superior and Δ75Inferior  indicated that the position of the measured 75% 
isodose line fell inside the planned 75% isodose line. Negative values of 75Superior and Δ75Inferior  indicated 























Infinity 1 Lung SBRT -0.6 -1.9 0.2 -0.9 -1.1 -0.5 
Infinity 1 Spine  SRS 0.0 -1.3 1.3 -0.9 -2.4 0.7 
 
 Table 3.12 contains the values of Δ60Left  and Δ60Right that correspond to the delivery of the spine 
SRS treatment plan shifted posteriorly by 2.0 or 2.7 cm on three different linear accelerators.  For either 
data session, 1 mm resolution was achieved in only the left-right direction.   
Table 3.12. Δ60Left  and Δ60Right  for posteriorly offset spine SRS profiles on three linear accelerators. 
Positive values of Δ60Left and Δ60Right  indicated that the position of the measured 60% isodose line fell 
inside the planned 60% isodose line. Negative values of 60Left and Δ60Right  indicated that the measured 























Infinity 1 Spine SRS, 2 cm -0.9 -1.6 -0.1 0.1 -0.5 1.0 
Versa HD Spine SRS, 2 cm -0.7 -1.2 0.2 -0.2 -0.5 0.5 
























Infinity 2 Spine SRS, 2cm -0.5 -0.9 0.0 -0.5 -0.8 0.0 
Infinity 1 Spine SRS, 2.7 cm -0.7 -2.3 0.4 -0.1 -2.8 1.7 
Versa HD Spine SRS, 2.7 cm -1.1 -2.0 1.1 -0.3 -2.7 0.9 
Infinity 2 Spine SRS, 2.7 cm 1.2 -0.7 3.3 0.0 -0.9 1.9 
 
3.4 Individual Gantry Beam Measurement Results  
 Tables 3.13 and 3.14 contain data for the delivery of individual gantry beams to the MapCHECK2 
diode array at its native resolution with MapPHAN shifted posteriorly in comparison with the TPS-
generated planar dose. These measurements were taken to provide more insight concerning the diode 
array’s performance and whether or not angular dependence and over-response were potential causes 
for dose discrepancies in the region of the spinal cord. Specifically, Table 3.13 corresponds to data taken 
at the approximate region where the spinal cord ROI is adjacent to the vertebral body, whereas Table 
3.14 corresponds to measurements taken at the approximate region representing the center of the spinal 
cord. Both measurement sessions displayed in Tables 3.13 and 3.14 resulted in overall high percent 
differences indicating that there was a systematically higher dose delivered to the region of the spinal 
cord for every prescribed gantry beam. Additional measurements were taken with the gantry and 
collimator placed at 0° to determine if angular dependence was the cause of the consistently higher dose 
delivered than planned.  
Table 3.13. SSRS beams at planned gantry angles delivered to a diode array shifted posteriorly by 2 cm 










100 85.19 38.93 118.83% 
120 159.73 88.12 81.26% 
140 207.98 171.87 21.01% 
160 165.97 125.75 31.98% 
180 59.83 51.97 15.12% 
200 179.92 152.65 17.86% 
220 241.16 175.19 37.66% 
240 128.39 51.67 148.48% 
260 91.69 31.79 188.42% 
Total 1319.86 887.94 48.64% 
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Table 3.14. SSRS beams at planned gantry angles delivered to a diode array shifted posteriorly by 2.7 










100 13.69 10.81 26.64% 
120 42.11 23.76 77.23% 
140 67.30 38.70 73.90% 
160 149.19 120.37 23.94% 
180 61.31 52.86 15.99% 
200 145.86 133.06 9.62% 
220 85.33 45.43 87.83% 
240 32.15 19.84 62.05% 
260 16.94 14.27 18.71% 
Total 613.88 459.10 33.71% 
 
 Table 3.15 displays the comparison between the TPS-generated planar dose and the data 
collected for the individual beams of the SSRS treatment plan delivered at gantry and collimator angles of 
0°. Delivering the treatment beams at these angles ostensibly eliminated any angular dependence of the 
diode array since the beams were delivered perpendicularly to the diode array. However, these 
measurements resulted in varying percent differences ranging from approximately -35% to 37% when the 
beams were delivered perpendicularly incident to the diode array, as is its intended use. The results from 
Table 3.15 suggest that angular dependence was not the cause of the systematic error seen in Tables 
3.13 and 3.14 where the beams were delivered at the prescribed angles.  











100 124.12 90.09 37.77% 
120 312.27 252.31 23.76% 
140 752.61 773.76 -2.73% 
160 207.68 322.82 -35.67% 
180 49.00 47.79 2.53% 
200 327.35 428.34 -23.58% 
220 683.63 696.94 -1.91% 
240 325.30 324.9 0.12% 
260 326.42 343.92 -5.09% 
Total 3108.38 3208.87 -5.26% 
 
Further analysis of the SSRS treatment beams delivered at 0° for the gantry and collimator angle 
led to the discovery that a 1-mm applied shift of the planar dose along the patient superior-inferior axis 
resulted in smaller percent differences, as seen in Table 3.16. This shift most likely accounted for gantry 
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sag that is prominent when the gantry is at 0° and 180°. With this shift applied, the delivery performance 
of the SSRS beams were closer to what was expected based on the treatment planning system. 
However, there was still variability as high as -12% between what was planned and what was measured 
on the diode array. In order to confirm if this finding was a result of the chosen diode array dosimeter or a 
result of an inaccuracy in the treatment planning system, a different experimental setup utilizing an ion 
chamber dosimeter was used to measure the delivered dose for the same set of gantry angle 
configurations as previously described.  
Table 3.16. SSRS beams delivered at gantry angle 0 and collimator angle 0 to a diode array on Versa HD 
linear accelerator. TPS Data was shifted by 1 mm along the Y-axis using SNC Patient™ Software, 










100 124.12 116.75 6.31% 
120 312.27 291.41 7.16% 
140 752.61 770.17 -2.28% 
160 207.68 237.45 -12.54% 
180 49.00 44.77 9.44% 
200 327.35 351.66 -6.91% 
220 683.63 687.78 -0.60% 
240 325.30 329.42 -1.25% 
260 326.42 333.58 -2.15% 
Total 3108.38 3162.99 -1.73% 
 
3.5 Ion Chamber Measurements  
 Tables 3.17 and 3.18 contain the data acquired using an ion chamber in the solid water “cheese” 
phantom at the specific points that represent the perimeter of the spinal cord ROI (Table 3.17) and center 
of the spinal cord (Table 3.18) as they compare to the TPS-generated values at the corresponding points 
of interest. These measurements were acquired with the beams at their planned gantry and collimator 
angles. The percent difference between the measured and planned values at both posterior positions was 
not negligible with regards to the anatomical point of interest they represent. Moreover, the consistently 
higher dose delivered agrees with the results from the central diode measurements seen in Tables 3.13 
and 3.14. The data from the ion chamber measurements shown in Tables 3.17 and 3.18 confirmed that 
the delivered dose measured by the diode array was valid, therefore suggesting an error in the treatment 
planning system’s beam modeling algorithm. 
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Table 3.17. Ion chamber measurements for an active detector volume representing the approximate 
region where the spinal cord ROI is adjacent to the vertebral body (2 cm from the CTV isocenter). Beams 


















100 93.33 30.1 132.9 72.2 27.5 29.27% 
120 150.43 41.4 253.1 120.9 51.3 24.43% 
140 151.98 77.8 221.3 134.0 30.7 13.42% 
160 118.33 56.8 128.6 89.2 23.6 32.66% 
180 47.48 38.3 49.7 43.3 3.4 9.65% 
200 133.37 94.4 171.8 123.9 18.2 7.64% 
220 163.78 56.7 280.5 147.6 54.5 10.96% 
240 100.32 31.1 191.8 75.9 39.0 32.17% 
260 107.04 27.8 156.9 60.0 27.0 78.40% 
Total 1066.06   867.0  22.96% 
 
Table 3.18. Ion chamber measurements for an active detector volume representing the approximate 
center of the spinal cord (2.7 cm from the CTV isocenter). Beams were delivered at their planned gantry 


















100 16.02 11.4 18.2 14.0 1.5 14.46% 
120 28.26 15.9 37.3 21.8 4.0 29.62% 
140 44.89 22.7 69.0 39.3 8.4 14.21% 
160 97.73 59.6 118.6 85.9 15.5 13.77% 
180 49.62 39.9 51.8 45.1 3.6 10.02% 
200 115.05 86.7 125.8 105.2 8.9 9.36% 
220 59.48 29.9 84.0 43.3 10.2 37.37% 
240 22.60 14.8 22.9 17.8 1.7 4.80% 
260 20.09 14.2 23.4 17.6 1.9 14.16% 
Total 453.73   390.0  16.34% 
 
To further test the accuracy of the SSRS treatment plan beams’ delivery, the beams were 
overridden to be delivered at gantry and collimator angles of 0° with the ion chamber placed 2.7 cm 
posterior to isocenter to represent the center of the spinal cord. Table 3.19 displays the result of this 
experiment where an improvement between the percent difference of the measured and calculated dose 
to this region of interest can be seen. The results in Table 3.19 suggest that the prescribed gantry and 
collimator angles for the SSRS treatment plan, in combination with the optimized modulation, are the 





Table 3.19. Ion chamber measurements for an active detector volume representing the approximate 
center of the spinal cord (2.7 cm from the CTV isocenter). Beams were overridden to be delivered at 


















100 64.60 26.4 89.6 59.0 22.2 9.49% 
120 176.80 109.4 216.0 161.6 37.0 9.41% 
140 437.40 408.1 443.5 428.1 10.2 2.17% 
160 158.40 70.7 267.1 164.8 60.6 -3.88% 
180 35.50 29.6 37.7 33.3 2.5 6.61% 
200 225.30 150.2 309.5 229.7 59.3 -1.92% 
220 409.90 368.2 416.9 396.7 12.2 3.33% 
240 195.90 177.8 203.0 188.7 7.3 3.82% 
260 200.98 183.4 212.4 196.7 9.8 2.18% 




Chapter 4. Discussion  
4.1 Summary of Results 
 This project provided quantitative data regarding the accuracy and precision of high-dose 
treatments delivered with the Elekta Infinity and Versa HD linear accelerators. Baseline geometric 
accuracy was established across all three linear accelerators through the MV isocenter accuracy test, 
which produced results for the radius of isocenter within the limits of the vendor-provided protocol for two 
of the three tested linear accelerators with the third linear accelerator’s isocenter radius varying by only 
0.01 mm from the limit.  Accuracy of dose delivery for two stereotactic treatment plans was assessed 
through a novel quality assurance platform that allowed for the diode array to achieve 1-mm resolution 
along one axis. The reproducibility of the experimental design was measured and found to have 
acceptable positional alignment errors and shift in isodose levels of less than 1 mm.  
 Variability in delivery accuracy of the treatment plans occurred across all three linear 
accelerators. Profile comparisons of the calculated and measured data from these measurements were 
analyzed for characteristic positional alignment (Δc). For the delivery of lung SBRT treatment plans, 2-
mm accuracy for patient setup with the use of immobilization devices has previously been achieved 
(Benedict et al., 2010; Wulf et al., 2000; Nagata et al., 2002). Our study proved the Elekta Infinity and 
Versa HD linear accelerators were able to achieve 2-mm positional accuracy. The delivery of the spine 
SRS treatment plan across all linear accelerators achieved less than a 1-mm accuracy on average that 
has previously been reported for spine SBRT treatments (Guckenberger et al., 2007; Wang et al., 2008; 
Chang et al., 2004). Yenice et al reported that errors of 2 mm in magnitude can result in a significantly 
greater (>100%) dose to the spinal cord than planned (Yenice et al., 2003). The calculated percent 
difference between measured and calculated dose values at the region representative of the spinal cord 
reflected these findings. Even with kV-CBCT positioning, the difference between calculated and 
measured doses showed a delivered dose to the region of the spinal cord as much as 39% higher than 
intended. Therefore, achieving 1-mm positional accuracy is necessary when treating spine SRS cases so 
as to avoid delivering a greater dose to OARs than planned.  
Where the positional alignment varied among each linear accelerator, analysis of the differences 
in specific isodose levels (Δ75 and Δ60) showed that, overall, the measured profile point fell outside the 
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planned isodose line, meaning that the target volume was consistently covered with the prescribed dose 
compared to the TPS calculation.  The values of Δ75 and Δ60 varied by approximately 1.2 mm at most 
for the lung SBRT and spine SRS, suggesting variable coverage of the target volume for the delivered 
plan compared to that generated by the treatment planning system.  
After analysis of the measured and planned profiles, consistently higher delivered doses were 
seen for those planes taken through the region of interest representing the spinal cord. This was 
particularly noteworthy as a dose exceeding the maximum limit to the spinal cord could lead to paralysis. 
Further investigation was required to identify the reason for discrepancy between the planned and 
measured dose at the spinal cord region of interest. Angular dependence was ruled out by individually 
delivering the SSRS beams to the diode array and comparing the delivered dose to the calculations 
performed by the treatment planning system. Consistently higher doses were measured when the beams 
were at their prescribed gantry and collimator angles. Variable doses were measured when the beams 
were overridden to be delivered at gantry and collimator angles of 0°. Once a millimeter shift was applied 
to the data, presumably to account for gantry sag when the gantry is placed at 0°, the magnitude of the 
percent difference between measured and calculated dose points decreased for most delivered beams. 
The evaluation of the delivery of individual SSRS beams proved that the delivery system was capable of 
delivering the planned beams when the gantry and collimator angles were set to 0°, which indicates that 
the treatment planning system is possibly incapable of modeling the beam accurately for the combination 
of the prescribed gantry and collimator angles as well as the optimized modulation required for the SSRS 
plan.  
To confirm the discrepancy between the measured and calculated dose, a different experimental 
setup was adopted to repeat the measurements of the individual beams delivered to the diode array. Ion 
chamber measurements were taken at the approximate position of the spinal cord, specifically its 
perimeter proximal to the vertebral column and its center. Results confirmed the difference in the 
measured and delivered dose at the level of the spinal cord for the SSRS plan in that doses delivered 
were consistently higher for the prescribed gantry angles. The results from both the diode array and ion 
chamber experiments suggest an inaccuracy in the treatment planning system as it was utilized for the 
SSRS treatment plan.  
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4.2 Limitations of Work 
 This work was limited by 1-mm resolution along one axis. This prevented the use of 2-
dimensional metrics, such as gamma analysis, in assessing the delivery accuracy of the treatment 
systems. Additionally, artifacts were produced in the profiles due to over-responding diodes when 
measured files were combined for the aggregate file. These artifacts created a “smearing” effect that was 
a direct result of the dosimeter despite dose calibrations performed on the diode array before every 
measurement session. Lastly, this project lacks complete sets of data for the SSRS treatment delivery at 
2 and 2.7 cm posterior offsets along the patient superior-inferior axis.  
4.3 Evaluation of Hypothesis 
 Based on the findings of this project, the Elekta Infinity and Versa HD delivery systems were 
adequate for lung SBRT treatments but require further exploration for the commencement of spine SRS 
treatments at Mary Bird Perkins Cancer Center. The hypothesis of this project was that the Elekta Infinity 
and Versa HD linear accelerators would be sufficient for lung SBRT and spine SRS treatments as 
deemed by clinical standards.  While both treatment deliveries achieved 1-mm accuracy on average in 
terms of positional alignment and isodose level coverage, the delivery of the SSRS treatment plan 
resulted in a consistently higher delivered dose to the region of the spinal cord at the prescribed gantry 
and collimator angles.  
4.4 Future Work 
 The data in this research was obtained using a diode array with a novel setup allowing for 1-mm 
resolution. With this research design, major dose discrepancies were found between the measured and 
planned treatment plans. Further analysis with a different dosimeter confirmed these findings to be true 
and not a result of experimental design. Therefore, these findings suggest an inconsistency between the 
treatment planning system and the delivery system. Assessment of the treatment planning system as it 
applies to high dose single fraction treatments could be evaluated further. Moreover, additional treatment 
plans utilizing techniques other than 3D conformal and step and shoot IMRT could be tested on these 
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Figure A.1. Coronal left-right profile plots of Trials 1 and 2 taken through Y = 1 cm of the lung SBRT 




Figure A.2. Coronal left-right profile plots through Y = 1 cm of the lung SBRT treatment plan delivered on 
the Elekta Versa HD at the MBPCC Baton Rouge facility and the Elekta Infinity with Agility head located 




Figure A.3. Coronal left-right profile plots of Trials 1 and 2 taken through Y = 0.5 cm of the lung SBRT 




Figure A.4. Coronal left-right profile plots through Y = 0.5 cm of the lung SBRT treatment plan delivered 
on the Elekta Versa HD at the MBPCC Baton Rouge facility and the Elekta Infinity with Agility head 




Figure A.5. Coronal left-right profile plots of Trials 1 and 2 taken through Y = 0 cm of the lung SBRT 




Figure A.6. Coronal left-right profile plots through Y = 0 cm of the lung SBRT treatment plan delivered on 
the Elekta Versa HD at the MBPCC Baton Rouge facility and the Elekta Infinity with Agility head located 




Figure A.7. Coronal left-right profile plots of Trials 1 and 2 taken through Y = -0.5 cm of the lung SBRT 




Figure A.8. Coronal left-right profile plots through Y = -0.5 cm of the lung SBRT treatment plan delivered 
on the Elekta Versa HD at the MBPCC Baton Rouge facility and the Elekta Infinity with Agility head 




Figure A.9. Coronal left-right profile plots of Trials 1 and 2 taken through Y = -1 cm of the lung SBRT 




Figure A.10. Coronal left-right profile plots through Y = -1 cm of the lung SBRT treatment plan delivered 
on the Elekta Versa HD at the MBPCC Baton Rouge facility and the Elekta Infinity with Agility head 




Figure A.11. Coronal superior-inferior profile plots of Trials 1 and 2 taken through X = 1 cm of the lung 




Figure A.12. Coronal superior-inferior profile plots of Trials 1 and 2 taken through X = 0.5 cm of the lung 




Figure A.13. Coronal superior-inferior profile plots of Trials 1 and 2 taken through X = 0 cm of the lung 




Figure A.14. Coronal superior-inferior profile plots of Trials 1 and 2 taken through X = -0.5 cm of the lung 




Figure A.15. Coronal superior-inferior profile plots of Trials 1 and 2 taken through X = -1 cm of the lung 




Figure A.16. Coronal left-right profile plots of Trials 1 and 2 taken through Y = 1 cm of the spine SRS 




Figure A.17. Coronal left-right profile plots of Trials 1 and 2 taken through Y = 0.5 cm of the spine SRS 




Figure A.18. Coronal left-right profile plots of Trials 1 and 2 taken through Y = 0 cm of the spine SRS 




Figure A.19. Coronal left-right profile plots of Trials 1 and 2 taken through Y = -0.5 cm of the spine SRS 




Figure A.20. Coronal left-right profile plots of Trials 1 and 2 taken through Y = -1 cm of the spine SRS 




Figure A.21. Coronal superior-inferior profile plots of Trials 1 and 2 taken through X = 1 cm of the spine 




Figure A.22. Coronal superior-inferior profile plots of Trials 1 and 2 taken through X = 0.5 cm of the spine 




Figure A.23. Coronal superior-inferior profile plots of Trials 1 and 2 taken through X = 0 cm of the spine 




Figure A.24. Coronal superior-inferior profile plots of Trials 1 and 2 taken through X = -0.5 cm of the spine 




Figure A.25. Coronal superior-inferior profile plots of Trials 1 and 2 taken through X = -1 cm of the spine 




Figure A.27. Coronal left-right profile plots of Trials 1 and 2 taken through Y = 0 cm of the spine SRS 
treatment plan shifted posteriorly by 2 cm with kV-CBCT positioning and delivered on the Elekta Infinity 




Figure A.28. Coronal left-right profile plots through Y = 0 cm of the spine SRS treatment plan shifted 
posteriorly by 2 cm delivered on the Elekta Versa HD at the MBPCC Baton Rouge facility and the Elekta 




Figure A.29. Coronal left-right profile plots of Trials 1 and 2 taken through Y = 1 cm of the spine SRS 
treatment plan shifted posteriorly by 2 cm with kV-CBCT positioning and delivered on the Elekta Infinity 




Figure A.30. Coronal left-right profile plots through Y = 1 cm of the spine SRS treatment plan shifted 
posteriorly by 2 cm delivered on the Elekta Versa HD at the MBPCC Baton Rouge facility and the Elekta 




Figure A.31. Coronal left-right profile plots of Trials 1 and 2 taken through Y = 0.5 cm of the spine SRS 
treatment plan shifted posteriorly by 2 cm with kV-CBCT positioning and delivered on the Elekta Infinity 




Figure A.32. Coronal left-right profile plots through Y = 0.5 cm of the spine SRS treatment plan shifted 
posteriorly by 2 cm delivered on the Elekta Versa HD at the MBPCC Baton Rouge facility and the Elekta 




Figure A.33. Coronal left-right profile plots of Trials 1 and 2 taken through Y = -0.5 cm of the spine SRS 
treatment plan shifted posteriorly by 2 cm with kV-CBCT positioning and delivered on the Elekta Infinity 




Figure A.34. Coronal left-right profile plots through Y = -0.5 cm of the spine SRS treatment plan shifted 
posteriorly by 2 cm delivered on the Elekta Versa HD at the MBPCC Baton Rouge facility and the Elekta 




Figure A.35. Coronal left-right profile plots of Trials 1 and 2 taken through Y = -1 cm of the spine SRS 
treatment plan shifted posteriorly by 2 cm with kV-CBCT positioning and delivered on the Elekta Infinity 




Figure A.36. Coronal left-right profile plots through Y = - 1 cm of the spine SRS treatment plan shifted 
posteriorly by 2 cm delivered on the Elekta Versa HD at the MBPCC Baton Rouge facility and the Elekta 




Figure A.37. Coronal left-right profile plots of Trials 1 and 2 taken through Y = 0 cm of the spine SRS 
treatment plan shifted posteriorly by 2.7 cm with kV-CBCT positioning and delivered on the Elekta Infinity 




Figure A.38. Coronal left-right profile plots through Y = 0 cm of the spine SRS treatment plan shifted 
posteriorly by 2.7cm delivered on the Elekta Versa HD at the MBPCC Baton Rouge facility and the Elekta 




Figure A.39. Coronal left-right profile plots of Trials 1 and 2 taken through Y = 1 cm of the spine SRS 
treatment plan shifted posteriorly by 2.7 cm with kV-CBCT positioning and delivered on the Elekta Infinity 




Figure A.40. Coronal left-right profile plots through Y = 1 cm of the spine SRS treatment plan shifted 
posteriorly by 2.7cm delivered on the Elekta Versa HD at the MBPCC Baton Rouge facility and the Elekta 




Figure A.41. Coronal left-right profile plots of Trials 1 and 2 taken through Y = 0.5 cm of the spine SRS 
treatment plan shifted posteriorly by 2.7 cm with kV-CBCT positioning and delivered on the Elekta Infinity 




Figure A.42. Coronal left-right profile plots through Y = 0.5 cm of the spine SRS treatment plan shifted 
posteriorly by 2.7cm delivered on the Elekta Versa HD at the MBPCC Baton Rouge facility and the Elekta 




Figure A.43. Coronal left-right profile plots of Trials 1 and 2 taken through Y = -0.5 cm of the spine SRS 
treatment plan shifted posteriorly by 2.7 cm with kV-CBCT positioning and delivered on the Elekta Infinity 




Figure A.44. Coronal left-right profile plots through Y = -0.5 cm of the spine SRS treatment plan shifted 
posteriorly by 2.7cm delivered on the Elekta Versa HD at the MBPCC Baton Rouge facility and the Elekta 




Figure A.45. Coronal left-right profile plots of Trials 1 and 2 taken through Y = -1 cm of the spine SRS 
treatment plan shifted posteriorly by 2.7 cm with kV-CBCT positioning and delivered on the Elekta Infinity 




Figure A.46. Coronal left-right profile plots through Y = -1 cm of the spine SRS treatment plan shifted 
posteriorly by 2.7cm delivered on the Elekta Versa HD at the MBPCC Baton Rouge facility and the Elekta 
Infinity with Agility head located at the MBPCC Gonzales facility, respectively. 
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Appendix B. MV Isocenter Accuracy Test Data 
The data was analyzed with the RIT Isocenter Analysis Tool. The green circle represents the 
perimeter of the radiation field defined by the stereotactic cone with the green cross representing the 
center of the cone. Additionally, the blue circle delineates the edge of the BB with the blue cross 
representing the center of the BB. The maximum value of the first four numbers in the R (mm) deviation 
column represents the MV isocenter radius for gantry rotation. The maximum value of the eight numbers 
in the R (mm) column represents the radius of the MV isocenter on the gantry and the treatment table. 
 
Figure B.1. MV Isocenter analysis of the Elekta Infinity platform with Agility head located at the Baton 
Rouge MBPCC facility (Infinity 1). EPID mages were analyzed with the RIT Isocenter Analysis Tool for the 






Figure B.2. MV Isocenter analysis of the Versa HD™ platform located at the Baton Rouge MBPCC facility 
(Infinity 1). EPID mages were analyzed with the RIT Isocenter Analysis Tool for the four cardinal gantry 
angles with couch at 0° and four couch angles with gantry at 0°. 
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Figure B.3. MV Isocenter analysis of the Elekta Infinity platform with Agility head located at the Gonzales 
MBPCC facility (Infinity 2). EPID mages were analyzed with the RIT Isocenter Analysis Tool for the four 




Appendix C. Data from kV-CBCT Translations 
 Table C.1 displays the coordinates for the initial alignment of the MapCHECK2 array to the room 
lasers as well as the final suggested shifts provided by XVI after translation and kV-CBCT image 
registration to confirm the desired position was achieved. Even though the kV-CBCT registration 
algorithm is capable of identifying sub-millimeter shifts, the treatment table is only capable of millimeter 
adjustments. Therefore, 1 mm shifts are deemed acceptable and are not required to be executed. 
However, a tolerance of ±0.05 cm was set for the purpose of this study in accessing the accuracy of 
delivery. The data in Table 3.3 shows that the applied posterior shifts were within the acceptable range 
for data acquisition. 
Table C.1. Data acquired from the XVI kV-CBCT image registration used for assessing the positioning of 
the diode array before measurement sessions. 




















Shift, Trial 1 
on Infinity 1 
+0.03 +0.08 -0.04 +0.02 -0.03 -2.03 
SSRS 2cm 
Posterior 
Shift, Trial 2 
on Infinity 1 










+0.02 +0.04 -0.05 +0.02 -0.05 -2.05 
SSRS 2.7cm 
Posterior 
Shift, Trial 1 
on Infinity 1 
-0.05 -0.10 +0.05 +0.04 0.00 -2.73 
SSRS 2.7cm 
Posterior 
Shift, Trial 2 
on Infinity 1 
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